While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

Zepbound, which earned the nod in November 2023 ... It earned a high-dose (HD) formulation of Eylea in 2023 that decreased ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...

The weight loss drugs Ozempic and Wegovy may be beneficial for people struggling with alcohol addiction, a study published ...

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

GLP-1 drugs have been linked to numerous potential health benefits like treatment of existing conditions including heart ...